Ernexa Therapeutics Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Ernexa Therapeutics Inc. (ERNA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$995.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-29.
Discontinued › Income Statement
us-gaap:ProfitLoss · last filed 2013-03-29
- Ernexa Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2012-06-30 was -$633.00.
- Ernexa Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2011-06-30 was -$1.06K.
- Ernexa Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2012 was -$995.00K.
- Ernexa Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2011 was -$3.42M.
- Ernexa Therapeutics Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2010 was -$358.00K.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|
| 2012-12-31 | -$995.00K 10-K · filed 2013-03-29 | |||
| 2012-06-30 | -$633.00 10-Q · filed 2012-08-14 | -$1.68K 10-Q · filed 2012-08-14 | ||
| 2011-12-31 | -$3.42M 10-K · filed 2013-03-29 | -$3.26M 10-K · filed 2012-03-30 | ||
| 2011-06-30 | -$1.06K 10-Q · filed 2012-08-14 | -$1.61K 10-Q · filed 2012-08-14 | ||
| 2010-12-31 | -$358.00K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |